Identification and characterization of two consistent osteoarthritis subtypes by transcriptome and clinical data integration

Abstract Objective To identify OA subtypes based on cartilage transcriptomic data in cartilage tissue and characterize their underlying pathophysiological processes and/or clinically relevant characteristics. Methods This study includes n = 66 primary OA patients (41 knees and 25 hips), who underwent a joint replacement surgery, from which macroscopically unaffected (preserved, n = 56) and lesioned (n = 45) OA articular cartilage were collected [Research Arthritis and Articular Cartilage (RAAK) study]. Unsupervised hierarchical clustering analysis on preserved cartilage transcriptome followed by clinical data integration was performed. Protein–protein interaction (PPI) followed by pathway enrichment analysis were done for genes significant differentially expressed between subgroups with interactions in the PPI network. Results Analysis of preserved samples (n = 56) resulted in two OA subtypes with n = 41 (cluster A) and n = 15 (cluster B) patients. The transcriptomic profile of cluster B cartilage, relative to cluster A (DE-AB genes) showed among others a pronounced upregulation of multiple genes involved in chemokine pathways. Nevertheless, upon investigating the OA pathophysiology in cluster B patients as reflected by differentially expressed genes between preserved and lesioned OA cartilage (DE-OA-B genes), the chemokine genes were significantly downregulated with OA pathophysiology. Upon integrating radiographic OA data, we showed that the OA phenotype among cluster B patients, relative to cluster A, may be characterized by higher joint space narrowing (JSN) scores and low osteophyte (OP) scores. Conclusion Based on whole-transcriptome profiling, we identified two robust OA subtypes characterized by unique OA, pathophysiological processes in cartilage as well as a clinical phenotype. We advocate that further characterization, confirmation and clinical data integration is a prerequisite to allow for development of treatments towards personalized care with concurrently more effective treatment response.

[1]  Win Min Oo,et al.  Disease modification in osteoarthritis: are we there yet? , 2019, Clinical and experimental rheumatology.

[2]  Seung-Yoon Park,et al.  Ablation of Stabilin-1 Enhances Bone-Resorbing Activity in Osteoclasts In Vitro , 2019, Calcified Tissue International.

[3]  M. Reinders,et al.  RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage , 2018, Annals of the rheumatic diseases.

[4]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[5]  D. Gudbjartsson,et al.  Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis , 2018, Nature Genetics.

[6]  Tom R. Gaunt,et al.  Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank , 2018, bioRxiv.

[7]  J. Schwartz,et al.  Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage , 2017, Annals of the rheumatic diseases.

[8]  M. Karsdal,et al.  Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo , 2017, Journal of Translational Medicine.

[9]  M. Karsdal,et al.  Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. , 2017, Osteoarthritis and cartilage.

[10]  Camille Roth,et al.  Natural Scales in Geographical Patterns , 2017, Scientific Reports.

[11]  M. Karsdal,et al.  Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. , 2016, Osteoarthritis and cartilage.

[12]  Ashutosh Kumar Singh,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[13]  C. Weston,et al.  Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury , 2016, Proceedings of the National Academy of Sciences.

[14]  F. Beier,et al.  Targeting oxidative stress to reduce osteoarthritis , 2016, Arthritis Research & Therapy.

[15]  W. Cao,et al.  Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis , 2015, Arthritis Research & Therapy.

[16]  S. Bierma-Zeinstra,et al.  Distinct subtypes of knee osteoarthritis: data from the Osteoarthritis Initiative. , 2015, Rheumatology.

[17]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[18]  Malika Charrad,et al.  NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set , 2014 .

[19]  J. Goeman,et al.  Genes Involved in the Osteoarthritis Process Identified through Genome Wide Expression Analysis in Articular Cartilage; the RAAK Study , 2014, PloS one.

[20]  F. Eckstein,et al.  Intraarticular Sprifermin (Recombinant Human Fibroblast Growth Factor 18) in Knee Osteoarthritis: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2014, Arthritis & rheumatology.

[21]  G. Ramesh.  Novel Therapeutic Targets in Neuroinflammation and Neuropathic Pain. , 2014, Inflammation and cell signaling.

[22]  F. Casares,et al.  Several Cis-regulatory Elements Control mRNA Stability, Translation Efficiency, and Expression Pattern of Prrxl1 (Paired Related Homeobox Protein-like 1)* , 2013, The Journal of Biological Chemistry.

[23]  Fernando Rivadeneira,et al.  Bone parameters across different types of hip osteoarthritis and their relationship to osteoporotic fracture risk. , 2013, Arthritis and rheumatism.

[24]  Richard J. Miller,et al.  CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis , 2012, Proceedings of the National Academy of Sciences.

[25]  D. Knol,et al.  Identification of phenotypes with different clinical outcomes in knee osteoarthritis: Data from the osteoarthritis initiative , 2011, Arthritis care & research.

[26]  Bin Zhang,et al.  Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R , 2008, Bioinform..

[27]  D. Ornitz,et al.  FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. , 2007, Developmental biology.

[28]  Ming Fan,et al.  SamCluster: An Integrated Scheme for Automatic Discovery of Sample Classes Using Gene Expression Profile , 2003, Bioinform..

[29]  R. Kurzrock.  rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. , 2000, Oncology.

[30]  R. Kurzrock,et al.  Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.